作者
Andrea Cercek, Thomas Boerner, Benjamin R Tan, Joanne F Chou, Mithat Gönen, Taryn M Boucher, Haley F Hauser, Richard KG Do, Maeve A Lowery, James J Harding, Anna M Varghese, Diane Reidy-Lagunes, Leonard Saltz, Nikolaus Schultz, T Peter Kingham, Michael I D’Angelica, Ronald P DeMatteo, Jeffrey A Drebin, Peter J Allen, Vinod P Balachandran, Kian-Huat Lim, Francisco Sanchez-Vega, Neeta Vachharajani, Maria B Majella Doyle, Ryan C Fields, William G Hawkins, Steven M Strasberg, William C Chapman, Luis A Diaz, Nancy E Kemeny, William R Jarnagin
发表日期
2020/1/1
期刊
JAMA oncology
卷号
6
期号
1
页码范围
60-67
出版商
American Medical Association
简介
Importance
Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients.
Objective
To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC.
Design, Setting, and Participants
A single-institution, phase 2 clinical trial including 38 patients was conducted with HAI floxuridine plus systemic gemcitabine and oxaliplatin in patients with unresectable IHC at Memorial Sloan Kettering Cancer Center between May 20, 2013, and June 27, 2019. A confirmatory phase 1/2 study using the same therapy was conducted during the same time period at Washington University in St Louis. Patients with histologically confirmed, unresectable IHC were eligible. Resectable metastatic disease to …
学术搜索中的文章
A Cercek, T Boerner, BR Tan, JF Chou, M Gönen… - JAMA oncology, 2020